Loraz and Vinorelbine drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Loraz (lorazepam) and Vinorelbine (vinorelbine). Common drug interactions include chest pain among females and obstructive airways disorder among males.

The phase IV clinical study analyzes what interactions people have when they take Loraz and Vinorelbine. It is created by eHealthMe based on reports of 74 people who take the same drugs from the FDA, and is updated regularly.

What is Loraz?

Loraz has active ingredients of lorazepam. It is often used in stress and anxiety. eHealthMe is studying from 165,694 Loraz users. Check the latest studies of Loraz.

What is Vinorelbine?

Vinorelbine has active ingredients of vinorelbine. eHealthMe is studying from 6,381 Vinorelbine users. Check the latest studies of Vinorelbine.



On Jul, 29, 2026

74 people who take Loraz and Vinorelbine together, and have interactions are studied.

Loraz and Vinorelbine drug interactions.

What are the common drug interactions of Loraz and Vinorelbine, by gender? *:

female:

  1. Chest pain
  2. Bone pain
  3. C-reactive protein increased
  4. Chills (felling of cold)
  5. Disease progression
  6. Dyspnoea exertional (breathlessness or shortness of breath)
  7. Metastases to lymph nodes (cancer spreads to lymph node)
  8. Mucosal inflammation (infection of mucous membrane)
  9. Neoplasm progression (growth of tumour)
  10. Neutropenia (an abnormally low number of neutrophils)

male:

  1. Obstructive airways disorder (a progressive disease that makes it hard to breathe)
  2. Hyperphosphataemia (electrolyte disturbance in which there is an abnormally elevated level of phosphate in the blood)
  3. Hypophosphataemia (electrolyte disturbance in which there is an abnormally low level of phosphate in the blood)
  4. Weight decreased
  5. Haematemesis (vomiting of blood)
  6. Immunodeficiency
  7. Organising pneumonia (pathologically by the presence in the distal air spaces of buds of granulation tissue)
  8. Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets)
  9. Tumour lysis syndrome (a group of metabolic complications that can occur after treatment of cancer, these complications are caused by the breakdown products of dying cancer cells)
  10. Abdominal pain

What are the common drug interactions of Loraz and Vinorelbine, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

  1. Hyperphosphataemia (electrolyte disturbance in which there is an abnormally elevated level of phosphate in the blood)
  2. Neoplasm progression (growth of tumour)
  3. Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets)
  4. Tumour lysis syndrome (a group of metabolic complications that can occur after treatment of cancer, these complications are caused by the breakdown products of dying cancer cells)
  5. Abdominal pain
  6. Immunodeficiency

10-19:

  1. Acute lymphocytic leukaemia (cancer of the white blood cells)
  2. Blood pressure increased
  3. Contusion (a type of hematoma of tissue in which capillaries)
  4. Diarrhoea
  5. Epistaxis (bleed from the nose)
  6. Haematemesis (vomiting of blood)
  7. Nausea (feeling of having an urge to vomit)
  8. Oral candidiasis (fungal infection of mouth)
  9. Pain in extremity
  10. Pyrexia (fever)

20-29:

  1. Obstructive airways disorder (a progressive disease that makes it hard to breathe)
  2. Obliterative bronchiolitis (bronchiolar inflammation)
  3. Organising pneumonia (pathologically by the presence in the distal air spaces of buds of granulation tissue)

30-39:

  1. Breast pain
  2. Cough
  3. Musculoskeletal chest pain (pain in chest muscle or nerve or bones)
  4. Pleural effusion (water on the lungs)
  5. Pneumonia
  6. Pseudomonas infection (pseudomonas infection is caused by a bacterium, pseudomonas aeruginosa)
  7. Ureteric obstruction
  8. Pneumothorax (the presence of air or gas in the cavity between the lungs and the chest wall, causing collapse of the lung)

40-49:

  1. Tubulointerstitial nephritis (a form of nephritis affecting the interstitium of the kidneys surrounding the tubules)
  2. Vomiting
  3. Diarrhoea
  4. Disease progression
  5. Dyspnoea (difficult or laboured respiration)
  6. Fatigue (feeling of tiredness)
  7. Gingival bleeding (bleeding gums)
  8. Headache (pain in head)
  9. Hypoaesthesia (reduced sense of touch or sensation)
  10. Iodine allergy

50-59:

  1. Bradycardia (abnormally slow heart action)
  2. Breast cancer
  3. Calcium ionised increased
  4. Cardiovascular disorder (heart diseases)
  5. Cerebrovascular accident (sudden death of some brain cells due to lack of oxygen when the blood flow to the brain is impaired by blockage or rupture)
  6. Chest pain
  7. Constipation
  8. Dehydration (dryness resulting from the removal of water)
  9. Diarrhoea
  10. Disease progression

60+:

  1. Headache (pain in head)
  2. Polyneuropathy (neurological disorder that occurs when many peripheral nerves throughout the body malfunction simultaneously)
  3. Nausea (feeling of having an urge to vomit)
  4. Bone pain
  5. C-reactive protein increased
  6. Chills (felling of cold)
  7. Dyspnoea exertional (breathlessness or shortness of breath)
  8. Epistaxis (bleed from the nose)
  9. Myalgia (muscle pain)
  10. Osteonecrosis of jaw (death of bone of jaw)

What are the existing conditions these people have? *

  1. Nausea (feeling of having an urge to vomit): 23 people, 31.08%
  2. Constipation: 22 people, 29.73%
  3. Insomnia (sleeplessness): 21 people, 28.38%
  4. Breast Cancer Metastatic: 20 people, 27.03%
  5. Ventricular Extrasystoles (premature cardiac contraction): 15 people, 20.27%
  6. Oral Candidiasis (fungal infection of mouth): 15 people, 20.27%
  7. Respiratory Tract Infection: 15 people, 20.27%
  8. Breast Cancer: 13 people, 17.57%
  9. Hepatic Pain (pain in liver): 13 people, 17.57%
  10. Back Pain: 13 people, 17.57%

* Approximation only. Some reports may have incomplete information.

Do you take Loraz and Vinorelbine?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Loraz and Vinorelbine:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Loraz:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Vinorelbine:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Loraz and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Vinorelbine and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies


How the study uses the data?

The study uses data from the FDA. It is based on lorazepam and vinorelbine (the active ingredients of Loraz and Vinorelbine, respectively), and Loraz and Vinorelbine (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: